Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;643(8074):1428-1438.
doi: 10.1038/s41586-025-09186-6. Epub 2025 Jun 18.

Allosteric modulation and biased signalling at free fatty acid receptor 2

Affiliations

Allosteric modulation and biased signalling at free fatty acid receptor 2

Xuan Zhang et al. Nature. 2025 Jul.

Abstract

Free fatty acid receptor 2 (FFA2) is a G protein-coupled receptor (GPCR) that is a primary sensor for short-chain fatty acids produced by gut microbiota. Consequently, FFA2 is a promising drug target for immunometabolic disorders1-4. Here we report cryogenic electronic microscopy structures of FFA2 in complex with two G proteins and three distinct classes of positive allosteric modulators (PAMs), and describe noncanonical activation mechanisms that involve conserved structural features of class A GPCRs. Two PAMs disrupt the E/DRY activation microswitch5 and stabilize the conformation of intracellular loop 2 by binding to lipid-facing pockets near the cytoplasmic side of the receptor. By contrast, the third PAM promotes the separation of transmembrane helices 6 and 7 by interacting with transmembrane helix 6 at the receptor-lipid interface. Molecular dynamic simulations and mutagenesis experiments confirm these noncanonical activation mechanisms. Furthermore, we demonstrate the molecular basis for the Gi versus Gq bias, which is due to distinct conformations of intracellular loop 2 stabilized by different PAMs. These findings provide a framework for the design of tailored GPCR modulators, with implications that extend beyond FFA2 to the broader field of GPCR drug discovery.

PubMed Disclaimer

Conflict of interest statement

Competing interests: G.M. and T.U. are co-founders and directors of Caldan Therapeutics ( https://www.caldantherapeutics.com/ ). G.M. is a co-founder and director of KelticPharmaTherapeutics ( https://keltic-pharma.com/ ). Both companies have interests in the development of FFA4 activators. The other authors declare no competing interests.

References

    1. Stoddart, L. A., Smith, N. J. & Milligan, G. International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol. Rev. 60, 405–417 (2008).
    1. Alvarez-Curto, E. & Milligan, G. Metabolism meets immunity: the role of free fatty acid receptors in the immune system. Biochem. Pharmacol. 114, 3–13 (2016).
    1. Kimura, I., Ichimura, A., Ohue-Kitano, R. & Igarashi, M. Free fatty acid receptors in health and disease. Physiol. Rev. 100, 171–210 (2020).
    1. McCarville, J. L., Chen, G. Y., Cuevas, V. D., Troha, K. & Ayres, J. S. Microbiota metabolites in health and disease. Annu. Rev. Immunol. 38, 147–170 (2020).
    1. Zhou, Q. et al. Common activation mechanism of class A GPCRs. eLife 8, e50279 (2019).

MeSH terms

Substances